Cue Biopharma Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cue Biopharma de 34.9% y 64.4% respectivamente, mientras que el BPA crecerá en un 35.5% al año.

Información clave

5.5%

Tasa de crecimiento de los beneficios

16.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	36.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Jun 10

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Jun 07

Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients

May 10

How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?

Mar 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CUE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	20	-35	N/A	N/A	3
12/31/2025	10	-39	N/A	N/A	4
12/31/2024	11	-40	N/A	N/A	4
6/30/2024	8	-47	-39	-39	N/A
3/31/2024	7	-50	-39	-39	N/A
12/31/2023	5	-51	-40	-40	N/A
9/30/2023	4	-52	-40	-40	N/A
6/30/2023	2	-52	-39	-39	N/A
3/31/2023	0	-52	-41	-41	N/A
12/31/2022	1	-53	-42	-42	N/A
9/30/2022	9	-47	-42	-42	N/A
6/30/2022	12	-49	-42	-42	N/A
3/31/2022	14	-46	-39	-39	N/A
12/31/2021	15	-44	-40	-39	N/A
9/30/2021	7	-47	-36	-35	N/A
6/30/2021	5	-44	-38	-36	N/A
3/31/2021	4	-44	-35	-33	N/A
12/31/2020	3	-45	-33	-32	N/A
9/30/2020	4	-43	-32	-32	N/A
6/30/2020	4	-40	-34	-33	N/A
3/31/2020	4	-38	-33	-33	N/A
12/31/2019	3	-37	-31	-31	N/A
9/30/2019	3	-39	-28	-28	N/A
6/30/2019	2	-45	-26	-25	N/A
3/31/2019	2	-43	-26	-25	N/A
12/31/2018	1	-39	-28	-26	N/A
9/30/2018	1	-38	-26	-24	N/A
6/30/2018	0	-30	-23	-22	N/A
3/31/2018	N/A	-27	N/A	-18	N/A
12/31/2017	N/A	-23	N/A	-12	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-10	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CUE siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CUE siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CUE siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (64.4% al año) de CUE crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (64.4% al año) de CUE crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CUE se prevé que sea elevada dentro de 3 años.

Cue Biopharma Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus estimates of losses per share improve by 20%

Price target decreased by 15% to US$8.00

Consensus revenue estimates increase by 17%

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 25%

Consensus revenue estimates decrease by 91%, EPS upgraded

Recent updates

Cue Biopharma, Inc. has filed a Follow-on Equity Offering.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Consensus estimates of losses per share improve by 20%

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 15% to US$8.00

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 20%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 25%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Share price stability

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 91%, EPS upgraded

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates fall by 24%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Consensus forecasts updated

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Consensus revenue estimates fall by 50%

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Consensus revenue estimates increase by 54%

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought US$105k worth of stock

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Consensus revenue estimates fall by 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Cue Biopharma: A First Assessment

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$24.83

CEO & Director exercised options and sold US$157k worth of stock

Consensus forecasts updated

Price target decreased to US$26.29

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma: Too Long To Arrive At Topline Trial Data

President & Chief Scientific Officer exercised options and sold US$173k worth of stock

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

CEO & Director exercised options and sold US$462k worth of stock

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT